Engineer 2 - Facilities

ElevateBio presented data at the ASGCT 29th Annual Meeting showcasing its expanded gene editing platform and services. The technology-driven advanced therapy CDMO demonstrated capabilities spanning targeted gene insertion using retrotransposon and machine learning-optimised recombinase approaches, plus a new epigenetic editing platform. The company's adenine base editors incorporate AI-designed functional deaminases, enabling targeting of previously inaccessible sites. Its proprietary lipid nanoparticle platform achieved therapeutically relevant in vivo editing across multiple modalities in mice and non-human primates, with favourable tolerability and demonstrated re-dosing capability. ElevateBio's platform spans multiple modalities including nucleases, base editors, reverse transcriptase editors, large gene insertion and epigenetic editors. These capabilities are supported by the company's cGMP manufacturing infrastructure, providing an integrated path from discovery through commercialisation for biopharmaceutical partners.

Sartorius launches next-generation platform to boost efficiency in cell therapy production. EQS-News: SARTORIUS AG / Key word(s): Product Launch Sartorius launches next-generation platform to boost efficiency in cell therapy production (news with additional features) 16.03.2026 / 14:04 CET/CEST The issuer is solely responsible for the content of this announcement. Göttingen, Germany | March 16, 2026 * Eveo Cell Therapy Platform enables automated, multi-parallel intensified production of autologous cell therapies * Compact design can increase output up to fourfold in existing cleanroom space * 90 percent reduction in manufacturing costs possible in CAR-T processes * Successful pilot project with CDMO ElevateBio proves applicability The life science group Sartorius is launching an integrated system for the production and quality control (QC) of autologous cell therapies. The modular Eveo Cell Therapy Platform is designed to address structural manufacturing bottlenecks that limit scalability and patient access to transformative treatments such as CAR-T therapies. With its latest innovation, Sartorius introduces a fundamentally new approach to cell therapy production that strengthens the company's position in the dynamic advanced therapies market. "Cell therapies are redefining medical possibilities. Yet, they remain accessible to only a small share of patients because manufacturing is complex, capacity-constrained and therefore expensive. With our integrated platform, we are tackling these structural bottlenecks head-on," said René Fáber, member of the Executive Board at Sartorius. "By combining raw materials, production equipment, software and QC assays into a scalable system, we enable our customers to expand output, significantly reduce cost per dose and shorten vein-to-vein time for patients." Conventional manufacturing models for autologous cell therapies rely on centralized, purpose-built facilities, that require significant greenfield investment, staff recruitment, training and multi-year build-up phases. Nevertheless, around 60 percent of regulatory disruptions in cell therapy production are caused by manufacturing and process-related issues. The new Eveo platform addresses these challenges by integrating cell selection, activation, gene modification, expansion, wash and concentration and final formulation into a closed system, using a variety of Sartorius solutions from critical raw materials to bioreactors and separation technologies. The system's compact design supports implementation in existing facilities with existing staff, allows for operation in lower-classification environments and supports centralized and decentralized manufacturing models. Sartorius has collaborated with ElevateBio, a leading cell therapy CDMO, amongst other partners, to test out the Eveo platform. In a successful pilot, the system performed in line with design expectations, demonstrating its real-world applicability. Due to its multi-parallel configuration, a single operator can process eight patient batches at once in the same cleanroom space traditionally needed for two batches. Assuming a manufacturing time of around seven days per batch and 50 production weeks per year, Eveo enables production of more than 350 doses per year in a footprint that today yields roughly 100 doses - an almost fourfold increase. Financial modelling confirms that the platform can reduce manufacturing costs by around 90 percent. Quality control also represents a major bottleneck in cell therapy production and release. With Sartorius' capabilities in live cell imaging and high throughput flow cytometry included in the Eveo platform, the technology addresses key analytical challenges and enables accessibility. Sartorius plans to begin taking orders for the Eveo Cell Therapy Platform in September 2026, with first deliveries expected in 2027. ElevateBio is a preferred partner and will be granted access to one of the first Eveo platforms for use with its manufacturing customers. More information about Eveo Cell Therapy Platform A profile of Sartorius Sartorius is a leading international partner to the biopharmaceutical research and manufacturing industries. The Lab Products & Services Division focuses on innovative laboratory instruments and consumables for research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies as well as academic research institutions. The Bioprocess Solutions Division supports customers with a broad product portfolio focused on single-use solutions for the safer, faster, and more sustainable production of biotech drugs, vaccines, and cell and gene therapies. With around 60 production and sales locations worldwide, the Göttingen-based company has a strong global presence. Sartorius regularly supplements its portfolio with acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3.5 billion euros. More than 14,000 employees serve customers around the globe. Leona Malorny Head of External Communications +49 551 308 4067 Additional features: 16.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. View original content: EQS News | Language: | English | | Company: | SARTORIUS AG | | / | Otto-Brenner-Straße 20 | | / | 37079 Göttingen | | / | Germany | | Phone: | +49.(0)551-308.0 | | Fax: | +49.(0)551-308.3289 | | E-mail: | [email protected] | | Internet: | www.sartorius.com | | ISIN: | DE0007165631, DE0007165607 | | WKN: | 716563, 716560 | | Indices: | MDAX, TecDAX | | Listed: | Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX | | EQS News ID: | 2291956 | | End of News | EQS News Service | 2291956 16.03.2026 CET/CEST

ElevateBio appoints Christopher Murphy as Chief Executive Officer and member of the Board of Directors. Christopher Murphy brings more than 35 years of industry experience in commercializing medicines, delivering profitable growth and biomanufacturing excellence. January 05, 2026 07:30 ET | Source: ElevateBio WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) - ElevateBio, a technology-driven company focused on powering the creation of life-transforming genetic medicines, today announced the appointment of Christopher Murphy as Chief Executive Officer (CEO) and member of its Board of Directors. He will succeed Ger Brophy, Ph.D., who has served as interim CEO since May 2025, and will continue to serve as an advisor on strategy and technology to the Company. Chris brings more than 35 years of leadership and operational experience across both biopharmaceutical and manufacturing sectors. He has a strong track record of combining expertise in advanced therapeutic development and manufacturing with commercial and operations management to accelerate revenue growth and build scalable businesses. His expertise will be instrumental in guiding ElevateBio's next phase of growth, focusing on scaling the business through new and expanded partnerships. "Chris is an exceptional fit to lead the ElevateBio team to capture the momentum of the genetic medicine industry's next wave of expansion," said David Hallal, Executive Chairman of ElevateBio. "His proven success and deep expertise in development and large-scale manufacturing are essential as more partners entrust us with their programs as they mature in development and require consistent, high-quality product for commercialization. I'd also like to thank Ger for his invaluable leadership and dedication as interim CEO and look forward to his continued guidance as a strategic advisor." Before joining ElevateBio, Chris served as CEO of Akron Bio, where he led a comprehensive transformation of the organization that drove robust revenue growth and valuation. Previously, he served as Chief Operating Officer of Brammer Bio, where he was responsible for the development and manufacture of viral vectors and led operations across four sites. The growth of the viral vector business led to the acquisition of Brammer Bio by Thermo Fisher Scientific in 2019, where Chris was responsible for integration and subsequently served as Vice President and General Manager of Viral Vector Services at Thermo Fisher. He has also held multiple leadership positions over his 16-year tenure at Sanofi Genzyme, where he was most recently responsible for managing the company's manufacturing site for Cerezyme(R). Chris received his M.S. in Biochemistry from New York Medical College and his B.S. in Biological Sciences from Rutgers University. "I am honored to join ElevateBio, a company that has firmly established itself as a leader in advanced therapies, built with a bold mission and a strong foundation," said Chris Murphy. "As the only company spanning genetic medicine design, development, and manufacturing, ElevateBio is uniquely positioned to move the cell and gene therapy field from scientific novelty to maturity. To take this next step, we will grow and expand partnerships across our manufacturing services and gene editing platform, industrialize workflows and establish new standards for the industry that make a tangible impact on the lives of patients and their families." About ElevateBio ElevateBio is a technology-driven company built to power transformative genetic medicines today and for many decades to come. The Company commercializes its enabling technologies, manufacturing capabilities, and industry-leading expertise through partnerships to accelerate development across a breadth of therapeutic approaches and modalities. The ElevateBio ecosystem combines Life Edit(R), its gene editing technologies and R&D business, with BaseCamp(R), its end-to-end genetic medicine process development and cGMP manufacturing business, to accelerate the discovery and development of advanced therapeutics. ElevateBio aims to be the dominant engine inside the world's greatest scientific advancements harnessing human cells and genes to alter disease. For more, visit https://elevate.bio or follow ElevateBio on LinkedIn or X. Release summary ElevateBio appoints Christopher Murphy as Chief Executive Officer and member of the Board of Directors.